CLINICAL TRIALS PROFILE FOR BELOTECAN

Clinical Trials for Belotecan

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00430144 ↗	Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix	Completed	Sokbom Kang	Phase 2	-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix
NCT00754858 ↗	Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer	Completed	Yonsei University	Phase 2	RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Belotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving belotecan together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well belotecan works when given together with cisplatin in treating patients with previously untreated extensive stage small cell lung cancer.
NCT00826644 ↗	Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	Completed	Chong Kun Dang Pharmaceutical	Phase 3	Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. Primary endpoints - to assess Response Rate Secondary endpoints - to assess Overall response duration, Time to progression, Overall survival
NCT00826644 ↗	Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	Completed	Chonnam National University Hospital	Phase 3	Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer. Primary endpoints - to assess Response Rate Secondary endpoints - to assess Overall response duration, Time to progression, Overall survival
NCT01022671 ↗	Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy	Completed	Asan Medical Center	Phase 2	A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.
NCT01022671 ↗	Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy	Completed	Samsung Medical Center	Phase 2	A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.
NCT01022671 ↗	Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy	Completed	Seoul National University Hospital	Phase 2	A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.

Clinical Trial Conditions for Belotecan

Condition Name

Condition Name
Intervention	Trials
Small Cell Lung Cancer	2
Carcinoma, Non-Small-Cell Lung	1
Carcinoma, Small Cell	1
Cervical Cancer	1

Condition MeSH

Condition MeSH
Intervention	Trials
Lung Neoplasms	4
Small Cell Lung Carcinoma	4
Squamous Cell Carcinoma of Head and Neck	1
Ovarian Neoplasms	1

Clinical Trial Locations for Belotecan

Trials by Country

Trials by Country
Location	Trials
Korea, Republic of	6
China	1

Clinical Trial Progress for Belotecan

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	1
Phase 2	5

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	6
RECRUITING	1
Unknown status	1

Clinical Trial Sponsors for Belotecan

Sponsor Name

Sponsor Name
Sponsor	Trials
Chong Kun Dang Pharmaceutical	4
Gachon University Gil Medical Center	1
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	9
Industry	4